| Name | MI-538 |
| Description | MI-538 is an interaction between menin and MLL fusion proteins inhibitor(IC50 of 21 nM). |
| In vitro | Treatment with MI-538 results in strong down regulation of expression of Hoxa9 and Meis1 genes. About 100 nM 27 was sufficient to reduce by ~50% Hoxa9 expression in MLL-AF9 cells, and even more pronounced effect was seen on Meis1 expression. |
| In vivo | Treatment with MI-538 leads to an approximately 80% reduction in MV4;11 tumor volume, with minimal toxicity, evidenced by less than a 10% decrease in body weight. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 10 mg/mL (17.65 mM), Sonication is recommended.
DMSO : 95 mg/mL (167.67 mM), Sonication is recommended.
|
| Keywords | MI-538 | MI538 | MI 538 | Menin-MLL | menin and MLL interaction | menin | Inhibitor | inhibit | HistoneMethyltransferase | Histone Methyltransferase | EpigeneticReaderDomain | Epigenetic Reader Domain |
| Inhibitors Related | MAK-683 hydrochloride | ABBV-744 | 3-methyl-1,2,3,4-tetrahydroquinazolin-2-one | (+)-JQ-1 | Tazemetostat | Piribedil | 5-Ph-IAA | Curcumin | EPZ015666 | Naphthol AS-E | MRTX-1719 | JQ-1 (carboxylic acid) |
| Related Compound Libraries | Methylation Compound Library | Histone Modification Compound Library | Reprogramming Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Epigenetics Compound Library | Chromatin Modification Compound Library | Inhibitor Library | PPI Inhibitor Library | Bioactive Compounds Library Max | Fluorochemical Library | Anti-Cancer Compound Library |
United States
